banner USF Home College of Arts & Sciences OASIS myUSF USF A-Z Index

USF Home > College of Arts and Sciences > Cancer Biology Ph.D. Program

Scott J. Antonia

Scott J. Antonia

Scott J. Antonia


Phone: 813/745-3883



B.S., University of Connecticut, Biology 1982
Ph.D., University of Connecticut Health Center, Immunology 1987 M.D., University of Connecticut Health Center 1989
Internal Medicine Resident, Yale-New Haven Hospital
1989-1991 Medical Oncology Fellow, Yale School of Medicine 1991-1994
Post-doctoral Fellow, Section of Immunobiology, Yale School of Medicine 1992-1996
Associate Research Scientist, Yale School of Medicine 1994


Dr. Antonia directs a translational research program that has the overall goal of developing novel immunotherapeutic strategies for the treatment of cancer patients. The basic research component of the program is to perform preclinical proof-of-principle testing of new vaccines, and to determine the mechanisms by which the tumor microenvironment is hostile to T cells. The vaccines currently under development are a GM-CSF/CD40 ligand gene-modified tumor cell vaccine, and dendritic cell based vaccines. With respect to the study of the tumor microenvironment, indoleamine 2,3-dioxygenase (IDO) has been identified as a significant immunosuppressive enzyme produced by tumor cells. A competitive inhibitor of IDO is currently being developed as a tumor vaccine augmentation strategy. Optimization and safety testing of the vaccines and augmentation strategies in anticipation of FDA IND applications is also performed.

The clinical research component of the translational research program involves the testing of the vaccines and augmentation strategies in cancer patients. An infrastructure has been put into place to accomplish this. A diverse group of investigators at the H. Lee Moffitt Cancer Center needed to accomplish these logistically complex clinical trials has been formed, and a vaccine production facility that operates with standard operating procedures compliant with current good manufacturing practices is operational. A phase I B7-1 gene-modified autologous tumor cell vaccine trial involving patients with metastatic renal cell carcinoma has been completed, and the phase II trial in ongoing.